Differences in the topoisomerase I cleavage complexes formed by camptothecin and wakayin, a DNA-intercalating marine natural product

Anti-Cancer Drugs

Volumn 7, Issue 7, 1996, Pages 758-765

  Kokoshka, Jerry M ^a   Capson, Todd L ^b   Holden, Joseph A ^c   Ireland, Chris M ^b   Barrows, Louis R ^a  

^a UNIVERSITY OF UTAH   (United States)

^b UNIVERSITY OF UTAH   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Camptothecin; Cleavage complex; DNA intercalator; Topoisomerase I; Wakayin

Indexed keywords

CAMPTOTHECIN; DNA TOPOISOMERASE; DNA TOPOISOMERASE INHIBITOR; ETHIDIUM BROMIDE; INTERCALATING AGENT; NATURAL PRODUCT; RADIOISOTOPE;

ARTICLE; ASCIDIACEA; COMPLEX FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DNA BINDING; DNA CLEAVAGE; DNA SEQUENCE; DRUG ISOLATION; FRACTIONATION; MARINE ENVIRONMENT; PRIORITY JOURNAL; TEMPERATURE;

EID: 0029995669     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199609000-00007     Document Type: Article

References (23)

1. Von Hoff DD, Burris III HA, Eckardt J, et al. Preclinical and phase I trials of topoisomerase I inhibitors. Cancer Chemother Pharmacol 1994; 34: S41-5.
2. Fukuoka M, Masuda N. Clinical studies of irinotecan alone and in combination with cisplatin. Cancer Chemother Pharmacol 1994; 34: S105-11.
3. Wang JC. Recent studies of DNA topoisomerases. Biochim Biophys Acta 1987; 909: 1-9.
4. Champoux JJ. Strand breakage by the DNA untwisting enzyme results in covalent attachment of the enzyme to DNA. Proc Natl Acad Sci USA 1977; 74: 3800-4.
5. Kohn KW, Pommier Y, Kerrigan D, et al. Topoisomerase II as a target of anticancer drug action in mammalian cells. NCI Monogr 1987; 4: 61-71.
6. Schneider E, Hsiang Y-H, Liu LF. DNA topoisomerase as anticancer drug targets. Adv Pharmacol 1990; 21: 149-83.
7. Johnson RK, Hertzberg RP, Eng W-K, McCabe FL, Kingsbury WD, Hecht SM. Discovery and design of topoisomerase I inhibitors. Proc Am Cancer Ass 1992; 33: 593-4.
8. Copp BR, Ireland CM, Barrows LR. Wakayin: a novel pyrroloiminoquinone from the ascidian Clavelina sp. J Org Chem 1991; 56: 4596-7.
9. Radisky DC, Radisky ES, Barrows LR, Copp BR, Kramer RA, Ireland CM. Novel Cytotoxic topoisomerase II inhibiting pyrroloiminoquinones from Fijian sponges of the genus Zyzzya. J Am Cancer Soc 1993; 115: 1632-7.
10. Barrows LR, Radisky DC, Copp BR, et al. Makaluvamines, marine natural products, are active anti-cancer agents and DNA Topo II inhibitors. Anti-Cancer Drug Des 1993; 8: 333-47.
11. McDonald LA, Eldredge GS, Barrows LR, Ireland CM. Inhibition of topoisomerase II-mediated DNA cleavage by pyridoacridine alkaloids from a Cystodytes sp. ascidian: a mechanism for the apparent intercalator-induced inhibition of topoisomerase II. J Med Chem 1994; 37: 3819-27.
12. Holden JA, Rolfson DH, Low RL. DNA topoisomerase I from human placenta. Biochim Biophys Acta 1990; 1049: 303-10.
13. Swaffar DS, Ireland CM, Barrows LR. A rapid mechanism-based screen to detect potential anti-cancer agents. Anti-Cancer Drugs 1994, 5: 15-23
14. Rowe TC, Chen GL, Hsiang Y-H, Liu LF. DNA damage by antitumor acridines is mediated by mammalian DNA topoisomerase II. Cancer Res 1986; 46: 2021-6.
15. Hsiang Y-H, Hertzberg RP, Hecht S, Liu LF. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 1985; 260: 14873-8.
16. Been MD, Burgess RR, Champoux JJ. Nucleoside sequence preference at rat liver and wheat germ type 1 DNA topoisomerase breakage sites in duplex SV 40 DNA. Nucleic Acids Res 1984; 12: 3097-114.
17. Jaxel C, Kohn KW, Pommier Y Topoisomerase I interaction with SV40 DNA in the presence and absence of camptothecin. Nucleic Acids Res 1988; 16: 11157-71.
18. Hertzberg RP, Caranfa MJ, Hecht SM. On the mechanism of topoisomerase I inhibition by camptothecin: evidence for binding to an enzyme-DNA complex. Biochemistry 1989; 28: 4629-38.
19. Champoux JJ, Aronoff R. The effects of camptothecin on the reaction and the specificity of the wheat germ type I topoisomerase. J Biol Chem 1989; 264: 1010-5.
20. Hertzberg RP, Busby RW, Caranfa MJ, et al. Irreversible trapping of the DNA-topoisomerase I covalent complex. J Biol Chem 1990; 265: 19287-95.
21. Chen AY, Yu C, Gatto B, Liu LF. DNA minor groove-binding ligands: a different class of mammalian DNA topoisomerase I inhibitors. Proc Natl Acad Sci USA 1993; 90: 8131-5.
22. Larsen AK, Grondard L, Couprie J. et al. The antileukemic alkaloid fagaronine is an inhibitor of DNA topoisomerase I and II. Biochem Pharmacol 1993; 46: 1403-12.
23. Elsea SH, McGuirk PR, Gootz P, Moynihan M, Osheroff N. Drug features that contribute to the activity of quinolones against mammalian topoisomerase II and cultured cells: correlation between enhancement of enzyme-mediated DNA cleavage in vitro and cytotoxic potential. Antimicrob Agents Chemother 1993; 37: 2599-605.